Need an investment idea? Check out Popular Stocks and S2O Stock Screener.

Market Price

0.20 

0.00 0.0%

as of Sep 27 '22

52 Week Range:

0.19 0.82


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. The company is headquartered in Calgary, Canada.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Apr '12 Apr '13 Apr '14 Apr '15 Apr '16 Apr '17 Apr '18 Apr '19 Apr '20 Oct '20 Dec '21
Equity (BVPS) 0.04
-0.27
-0.86
-0.77
-0.56
-1.17
-0.57
-1.05
-0.49
-0.23
growth rate -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Earnings BIT -20.83
-50.14
-13.54
-8.46
-19.69
-34.03
-41.56
-38.74
-21.96
-14.57
-15.94
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Avg.PE 5.48
0.89
83.33
83.33
-3.17
-3.03
-3.03
-3.03
-3.03
-3.03
growth rate -59.7% 9,262.9% 0.0% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ROA -180.62
263.82
-468.53
151.54
-64.37
-181.34
-609.14
853.24
-239.47
growth rate 100.0% -100.0% 100.0% -100.0% 0.0% 0.0% 100.0% -100.0%
ROE -533.52
growth rate
ROIC -535.04
growth rate
Cur. Ratio 1.08
0.82
0.20
0.83
2.49
0.08
0.11
0.12
0.11
0.17
growth rate -24.1% -75.6% 315.0% 200.0% -96.8% 37.5% 9.1% -8.3% 24.3%
Quick Ratio 0.83
0.75
0.13
0.81
2.32
0.02
0.01
0.10
0.03
0.02
growth rate -9.6% -82.7% 523.1% 186.4% -99.1% -50.0% 900.0% -70.0% -18.4%
Leverage 4.51
growth rate
Balance Sheet Apr '12 Apr '13 Apr '14 Apr '15 Apr '16 Apr '17 Apr '18 Apr '19 Apr '20 Oct '20 Dec '21
Acct.Receivable 0.00
0.19
1.98
5.74
0.25
0.22
0.98
0.92
0.85
0.31
growth rate 962.4% 190.4% -95.7% -11.8% 352.8% -5.9% -7.8% -63.4%
Acct.Payable 1.00
0.89
4.94
12.16
22.20
8.19
7.88
6.94
8.70
growth rate -10.5% 454.7% 146.0% 82.7% -63.1% -3.8% -11.9% 25.4%
Cur.Assets 11.60
21.31
1.05
18.75
36.48
5.65
4.04
10.64
3.18
1.94
2.95
growth rate 83.7% -95.1% 1,689.0% 94.6% -84.5% -28.5% 163.1% -70.1% -39.2% 52.5%
Total Assets 13.83
22.87
3.03
21.16
40.10
10.87
8.28
16.29
11.38
10.71
9.98
growth rate 65.3% -86.8% 599.1% 89.5% -72.9% -23.8% 96.8% -30.1% -5.9% -6.8%
Cash 8.48
19.41
0.59
16.21
28.11
1.36
0.12
7.69
0.00
0.09
0.01
growth rate 129.0% -97.0% 2,647.6% 73.4% -95.2% -91.1% 6,254.6% -100.0% 2,075.0% -93.1%
Inventory 0.89
0.22
0.32
1.85
3.34
3.06
1.16
1.55
0.58
2.45
growth rate -75.0% 20.1% 474.2% 80.8% -8.6% -62.2% 34.3% -62.4% 320.0%
Cur.Liabilities 10.71
25.99
5.77
22.35
14.61
69.74
37.96
86.61
28.69
11.76
17.42
growth rate 142.7% -77.8% 287.1% -34.6% 377.3% -45.6% 128.2% -66.9% -59.0% 48.1%
Liabilities 10.71
55.78
66.24
94.88
96.53
112.44
91.96
224.01
75.49
50.60
69.85
growth rate 420.8% 18.8% 43.2% 1.7% 16.5% -18.2% 143.6% -66.3% -33.0% 38.0%
LT Debt 0.00
29.78
60.47
72.54
81.92
42.70
54.00
137.40
45.80
38.00
50.70
growth rate 103.0% 20.0% 12.9% -47.9% 26.5% 154.4% -66.7% -17.0% 33.4%
Equity 3.01
-63.22
-73.73
-56.43
-101.57
-83.68
-207.72
-64.11
-39.90
-59.87
growth rate -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Common Shares 65.00
74.00
79.00
85.00
101.00
105.00
138.00
284.91
305.64
322.41
326.89
growth rate 13.9% 6.8% 7.6% 18.8% 4.0% 31.4% 106.5% 7.3% 5.5% 1.4%
Cash Flow Statement Apr '12 Apr '13 Apr '14 Apr '15 Apr '16 Apr '17 Apr '18 Apr '19 Apr '20 Oct '20 Dec '21
Capital Expenditures 0.11
0.33
0.79
0.22
0.03
0.02
0.01
0.01
0.01
growth rate 199.8% 134.9% -72.3% -88.1% -15.4% -63.6% 0.0% 62.5%
Cash Dividends 0.00
growth rate
Cash From OA -24.03
-13.19
-8.50
-21.42
-22.67
-25.13
-48.83
-17.34
-4.40
-8.02
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
FCF per Share -0.37
-0.37
-0.27
-0.15
-0.26
-0.31
-0.27
-0.32
-0.17
-0.02
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Sale Purchase of Stock 6.37
2.75
38.96
0.25
growth rate -56.9% 1,318.4% -99.4%
FCF -25.00
-30.00
-14.00
-10.00
-22.00
-23.00
-26.00
-49.00
-18.00
-9.00
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Income Statement Apr '12 Apr '13 Apr '14 Apr '15 Apr '16 Apr '17 Apr '18 Apr '19 Apr '20 Oct '20 Dec '21
Sales 0.00
growth rate
Op.Income -27.44
-38.60
-13.54
-8.46
-19.69
-34.03
-41.56
-38.74
-21.96
-14.57
-15.94
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
IBT -20.86
-50.20
55.19
-19.41
-19.70
-46.13
-58.26
-162.77
118.05
2.50
-24.76
growth rate 0.0% 100.0% -100.0% 0.0% 0.0% 0.0% 0.0% 100.0% -97.9% -100.0%
Net Income -20.97
-48.41
55.10
-18.32
-19.72
-46.21
-58.31
-162.80
118.03
2.46
-24.77
growth rate 0.0% 100.0% -100.0% 0.0% 0.0% 0.0% 0.0% 100.0% -97.9% -100.0%
EPS 0.29
0.58
-0.69
-0.22
-0.20
-0.44
-0.42
-0.87
0.54
-0.10
growth rate 100.0% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -100.0%
Gross Profit 0.00
growth rate
R&D 21.64
31.68
9.31
4.19
15.37
29.76
37.49
32.23
15.18
6.29
4.55
growth rate 46.4% -70.6% -55.0% 267.2% 93.7% 26.0% -14.0% -52.9% -58.6% -27.7%

Quarterly Statements

Item Name Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Earnings BIT -1.74
-3.40
-5.23
-5.57
-5.95
growth rate 0.0% 0.0% 0.0% 0.0%
Balance Sheet Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Acct.Receivable 0.46
0.66
0.93
0.31
0.16
growth rate 42.6% 41.0% -66.6% -48.4%
Acct.Payable 7.58
3.80
6.01
8.70
11.62
growth rate -50.0% 58.3% 44.8% 33.5%
Cur.Assets 1.21
4.90
4.17
2.95
3.26
growth rate 304.5% -14.9% -29.2% 10.5%
Total Assets 10.62
14.10
11.29
9.98
10.30
growth rate 32.8% -20.0% -11.6% 3.2%
Cash 0.03
3.20
0.40
0.01
0.48
growth rate 10,934.5% -87.4% -98.5% 7,900.0%
Inventory 0.58
0.62
2.54
2.45
2.43
growth rate 6.0% 311.0% -3.6% -1.1%
Cur.Liabilities 11.09
14.39
14.77
17.42
21.24
growth rate 29.8% 2.6% 18.0% 21.9%
Liabilities 49.82
52.75
54.81
69.85
70.92
growth rate 5.9% 3.9% 27.4% 1.5%
LT Debt 37.90
37.70
39.50
50.70
47.40
growth rate -0.5% 4.8% 28.4% -6.5%
Equity -39.20
-38.65
-43.52
-59.87
-60.62
growth rate 0.0% 0.0% 0.0% 0.0%
Common Shares 322.89
325.39
326.55
326.89
327.96
growth rate 0.8% 0.4% 0.1% 0.3%
Cash Flow Statement Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Capital Expenditures
growth rate
Cash From OA -0.19
-5.16
-2.48
-0.20
-1.19
growth rate 0.0% 0.0% 0.0% 0.0%
Sale Purchase of Stock
growth rate
FCF
growth rate
Income Statement Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Op.Income -1.74
-3.40
-5.23
-5.57
-5.95
growth rate 0.0% 0.0% 0.0% 0.0%
IBT 0.02
-2.60
-5.28
-16.90
-2.33
growth rate -100.0% 0.0% 0.0% 0.0%
Net Income 0.02
-2.61
-5.29
-16.90
-2.33
growth rate -100.0% 0.0% 0.0% 0.0%
EPS
growth rate
R&D 0.94
1.51
1.04
1.07
1.51
growth rate 61.2% -31.3% 3.6% 40.6%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

F (0.00)

YOY Growth Grade:

F (0.00)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 15.71 14.29 -1.00
EPS / Growth 0.0% 0.01

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 1.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 0.0% 0.5% 0.5%
Future PE 0.00 0.51 0.51
Future EPS 0.01 0.01 0.01
Value Price
MOS %
0.00
-100.0%
0.00
-99.1%
0.00
-99.1%
MOS Price 0.00 0.00 0.00
IRT 14.29 13.77 13.77

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.